The advanced lung cancer inflammation index (ALI), which is based on albumin (ALB), body mass index (BMI), and the neutrophil-to-lymphocyte ratio (NLR), was first developed by Jafri et al. and has been proven to be a novel inflammatory parameter for predicting the prognosis of patients with metastatic non-small cell lung cancer [7]. This evidence concerns the gene ALB and lung carcinoma.